[PDF] Top 20 Efeitos da massagem rápida no estresse em praticantes de atividade física
Has 10000 "Efeitos da massagem rápida no estresse em praticantes de atividade física" found on our website. Below are the top 20 most common "Efeitos da massagem rápida no estresse em praticantes de atividade física".
11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial.
... from HER2-positive early breast ...molecule HER2 inhibitor lapatinib combined with 1 year of trastuzumab12 did not find a clinically significant ...inhibitor after 1 year of ... See full document
15
Association of p27 and Cyclin D1 Expression and Benefit from Adjuvant Trastuzumab Treatment in HER2-Positive Early Breast Cancer: A TransHERA Study.
... the HERA study (Breast International Group [BIG] ...with HER2-positive (overexpressed or amplified) primary breast cancer (1), and who consented to evaluation of their tumor ... See full document
26
Herceptin® (trastuzumab) in HER2-positive early breast cancer: protocol for a systematic review and cumulative network meta-analysis
... “Chemotherapy, Adjuvant,” “Trastuzumab”) and keywords ...vant chemotherapy,” ...originator trastuzumab trial was initiated in 1992 in metastatic breast cancer, the ... See full document
92
Outcomes of re-treatment with first-line trastuzumab plus a taxane in HER2 positive metastatic breast cancer patients after (neo)adjuvant trastuzumab: A prospective multicenter study
... for HER2-positive early breast cancer (eBC) and metastatic breast cancer (mBC) [5, ...NOAH trial, treatment with trastuzumab plus chemotherapy showed ... See full document
210
Herceptin® (trastuzumab) in HER2-positive early breast cancer: a systematic review and cumulative network meta-analysis
... cycline-containing chemotherapy compared with H/ non-anthracycline-containing ...taining chemotherapy, due to the addition of clinical evi- dence from the North Central Cancer Treatment Group (NCCTG) ... See full document
5
Cost utility analysis of adjuvant trastuzumab therapy for HER2 positive early stage breast cancer in the Philippines
... cost-utility analysis (CUA) using deci- sion analytic Markov model to calculate and compare the costs and utilities of using 1 year of adjuvant tras- tuzumab combined with standard chemotherapy ... See full document
10
Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer.
... this adjuvant con- text must be weighed against the absolute risk of disease ...primary analysis. The median period of follow-up for this primary analysis was ...the trial ... See full document
5
Protein expression, survival and docetaxel benefit in node positive breast cancer treated with adjuvant chemotherapy in the FNCLCC PACS 01 randomized trial
... multivariate analysis when we applied a 15% cut-off (data not shown), regardless of the cut-off for ER and PR: 1% (P = ...tivariate analysis) when we used a 15% cut-off for Ki67 (Additional file 11, ... See full document
10
Dual HER2 blockade in the neoadjuvant and adjuvant treatment of HER2-positive breast cancer
... of breast tumors and has been associated with poor ...of trastuzumab in combination with standard chemotherapy in both early and advanced breast ...to trastuzumab may pose a ... See full document
24
Identifying patients at high risk of breast cancer recurrence: strategies to improve patient outcomes
... with early breast cancer to assess prognosis and increase precision of adjuvant ...spared chemotherapy and associated toxicity without com- promising survival and conversely patients in ... See full document
131
VEGF pathway targeting agents, vessel normalization and tumor drug uptake: from bench to bedside
... Translating preclinical insights about vessel normalization to the clinic has been challenging. This is due in part to the differences between tumor-bearing mice and human patients. Murine models with subcutaneous, ... See full document
119
HER2 amplification level is not a prognostic factor for HER2- positive breast cancer with trastuzumab-based adjuvant treatment: a systematic review and meta-analysis
... of HER2 amplification were associated with a significantly longer PFS or a significantly higher objective response rate (ORR) ...of HER2 amplification as a good predictive biomarker both for early ... See full document
11
tAnGo: a randomised phase III trial of gemcitabine in paclitaxel-containing, epirubicin/cyclophosphamide-based, adjuvant chemotherapy for early breast cancer: a prospective pulmonary, cardiac and hepatic function evaluation
... In 11 (8%) patients (6 EC-T; 5 EC-GT), ECHO/MUGA’s were categorised as having changed from normal to abnormal through- out ...Post- chemotherapy, LVEF returned to normal after this patient was ... See full document
69
Lapatinib, a TKI Dual Inhibitor of Her1 and Her2 Receptors: Review of the Literature
... recent years, probably owing to the prolonged survival of patients who underwent aggressive therapy for primary tumors, as well as improved technologies for detecting subclinical ...of breast cancer ... See full document
108
The effect of additional chemotherapy on high-risk prostate cancer: a systematic review and meta-analysis
... pooled analysis demonstrated that significant improvement in PFS was associated with additional chemo- therapy in high-risk PCa ...and chemotherapy on AR signaling. Docetaxel-based chemotherapy could ... See full document
13
Safety, activity, and molecular heterogeneity following neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer (Opti-HER HEART): an open-label, single-group, multicenter, phase 2 trial
... of trastuzumab and pertuzu- mab with ...TRYPHAENA trial, 75 patients received six cycles of trastuzumab and pertuzumab in combination with 5-fluorouracil, epirubicin, and cyclophosphamide (FEC) ... See full document
7
Cyclophosphamide metabolizing enzyme polymorphisms and survival outcomes after adjuvant chemotherapy for node positive breast cancer: a retrospective cohort study
... ever, this study of 124 subjects had only three individuals who carried a CYP3A4*1B variant and was thus under- powered to examine this association. Ambrosone and colleagues evaluated the role of GSTM1- and GSTT1- null ... See full document
9
ZFP42: A New Tumor Predisposition Gene? Presentation of a Patient with two Neoplasms in Childhood
... Chondrosarcoma is a tumor showing cartilaginous differentiation. Chondrocytes, the cartilage producing cells, are partly neural crest derived. It is the second most frequent bone tumor after osteosarcoma, ... See full document
12
Adjuvant Taxanes in Breast Cancer: A Critical Re appraisal
... a positive impact for taxanes in adjuvant breast cancer (BC) treatment in terms of reduced recurrence and ...taxane-containing adjuvant therapy for patients with early BC on OS, ... See full document
114
Generation of HER2 specific antibody immunity during trastuzumab adjuvant therapy associates with reduced relapse in resected HER2 breast cancer
... our analysis, and it also remains possible that patients in which we did not detect an antibody response in IgG λ may have mounted a response in IgG Κ or indeed other antibodies such as IgA or ...with HER2+ ... See full document
12
Related subjects